These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37377438)

  • 1. Production of a biosimilar version of aflibercept to improve VEGF blocker cytotoxicity on endothelial cells.
    Ramezani A; Zareinejad M; Mahmoudi Maymand E; Kaviani E; Ghaderi A
    Growth Factors; 2023 Aug; 41(3):140-151. PubMed ID: 37377438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes.
    Eissing T; Stewart MW; Qian CX; Rittenhouse KD
    Transl Vis Sci Technol; 2021 Apr; 10(4):9. PubMed ID: 34003985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Liu JN; Li JJ; Yan S; Zhang GN; Yi PS
    Front Oncol; 2023; 13():1074793. PubMed ID: 36910612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
    Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
    Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis.
    Wang X; He X; Qi F; Liu J; Wu J
    Front Pharmacol; 2022; 13():876386. PubMed ID: 35814207
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan.
    Yanagi Y; Takahashi K; Iida T; Gomi F; Morii J; Kunikane E; Sakamoto T
    Ophthalmol Ther; 2023 Aug; 12(4):2005-2021. PubMed ID: 37171557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
    Yamashita T; Kudo M; Ikeda K; Izumi N; Tateishi R; Ikeda M; Aikata H; Kawaguchi Y; Wada Y; Numata K; Inaba Y; Kuromatsu R; Kobayashi M; Okusaka T; Tamai T; Kitamura C; Saito K; Haruna K; Okita K; Kumada H
    J Gastroenterol; 2020 Jan; 55(1):113-122. PubMed ID: 31720835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma.
    Ito Y; Onoda N; Kudo T; Masuoka H; Higashiyama T; Kihara M; Miya A; Miyauchi A
    In Vivo; 2021; 35(2):1057-1064. PubMed ID: 33622902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability study over time of clinical solutions of ziv-aflibercept prepared in infusion bags using a proper combination of physicochemical and functional strategies.
    Hermosilla J; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Navas N
    J Pharm Biomed Anal; 2021 Sep; 203():114209. PubMed ID: 34153938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.
    Tomonari T; Sato Y; Tani J; Hirose A; Ogawa C; Morishita A; Tanaka H; Tanaka T; Taniguchi T; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Uchida K; Masaki T; Takayama T
    Hepatol Res; 2021 Apr; 51(4):472-481. PubMed ID: 33238074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of aflibercept (EYLEA
    Schicht M; Hesse K; Schröder H; Naschberger E; Lamprecht W; Garreis F; Paulsen FP; Bräuer L
    Ann Anat; 2017 May; 211():135-139. PubMed ID: 28279730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial.
    Woo SJ; Bradvica M; Vajas A; Sagong M; Ernest J; Studnicka J; Veith M; Wylegala E; Patel S; Yun C; Orski M; Astakhov S; Tóth-Molnár E; Csutak A; Enyedi L; Kim T; Oh I; Jang H; Sadda SR
    JAMA Ophthalmol; 2023 Jul; 141(7):668-676. PubMed ID: 37289448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
    Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial.
    Inatani M; Higashide T; Matsushita K; Miki A; Ueki M; Iwamoto Y; Kobayashi M; Leal S;
    Adv Ther; 2021 Feb; 38(2):1116-1129. PubMed ID: 33330958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of Aflibercept in the management of age-related macular degeneration.
    Hassan M; Afridi R; Sadiq MA; Soliman MK; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Expert Opin Biol Ther; 2016; 16(5):699-709. PubMed ID: 26982640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulodexide prevents activation of the PLA2/COX-2/VEGF inflammatory pathway in human retinal endothelial cells by blocking the effect of AGE/RAGE.
    Giurdanella G; Lazzara F; Caporarello N; Lupo G; Anfuso CD; Eandi CM; Leggio GM; Drago F; Bucolo C; Salomone S
    Biochem Pharmacol; 2017 Oct; 142():145-154. PubMed ID: 28651842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
    Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
    Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
    Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
    Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.